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Results: The MR-linac platform is in the last phase of the 
assessment. At its pre-defined imaging position in the linac 
room, the MR was shimmed and configured to work at peak 
performance. The linac’s radiation beam output was also 
found to be within specifications, being not affected by 
multiple passive exposures (testing over one year) to the 
MR’s magnetic fringe field. A hybrid MR-kV framework is 
under development to enable comprehensive RT tools for MR-
only RT planning, quantification of organ motion (fast 
imaging), in-room treatment guidance, and site specific 
adaptive RT workflows. QC procedures specific to the MR and 
linac integration were also developed for the mapping and 
correction of both scanner-related and patient-induced MR 
image distortions, mutual registration of the MR and linac 
isocenters, B0 mapping for monitoring the MR performance, 
4D MR, and generation of synthetic CT data sets. 
 
Conclusion: Key milestones of the MR and linac integration 
were achieved, supporting the feasibility of the system for 
clinical implementation.  
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Purpose or Objective: Locally advanced lung cancer lacks 
effective treatment options and may require aggressive 
chemo-radiotherapy (RT) with high doses. In the light of the 
RTOG 0617 trial, multi-centre dose escalation trials should 
avoid increasing organ at risk (OAR) toxicity and require strict 
quality assurance (QA). Dose escalation can be performed for 
sub volumes of the tumour by targeting of the most FDG-PET 
avid regions, and the planning target volume (PTV) can be 
reduced by implementing daily soft tissue based image-
guidance and adaptive RT. Incorporating these elements, the 
randomized multi-centre trial NARLAL2 by the Danish 
Oncologic Lung Cancer Group aims at increasing loco-regional 
control at 30 months without increasing toxicity. 
 
Material and Methods: In the standard arm, the PTV is 
treated with a homogenous dose of 66 Gy/33 fractions (fx). In 
the experimental arm, the dose is escalated heterogeneously 
to the FDG-PET avid volumes, with mean doses up to 95 
Gy/33 fx for the most PET active volumes of the primary 
tumour, and 74 Gy/33 fx for malignant lymph nodes ≥ 4 cm3. 
The escalation dose is limited in favour of OAR constraints. A 
standard and an experimental treatment plan are optimized 
for each patient prior to randomization. Dose to the lung in 
the experimental plan is kept similar to the lung dose in the 
standard plan. All enrolment centres were obliged to follow a 
strict QA program consisting of a treatment planning study, a 
soft tissue match and adaptive strategy workshop, and QA for 
PET scanners and FDG-PET volume delineation. In the present 
study, the dose distributions of the first 20 patients are 
analysed. The achieved dose escalation is compared to a 
previously conducted pilot study. 
 
 
 
Results: In the pilot study, the dose escalated FDG-PET avid 
part of tumour (PET GTV-T) and lymph nodes (PET GTV-N) 
received an average mean dose of 91.9 Gy and 72.1 Gy, 
respectively. The combined clinical target volume (CTV-total) 
received an average mean dose of 78.6 Gy. This corresponds 
to a 16 % estimated increase in loco-regional control at 30 
months. For the first 20 patients included, the experimental 
plan achieved an average mean dose of 92.3 Gy (SD 3.7) to 
PET GTV-T. A total of 11 large lymph nodes were escalated to 
an average mean dose of 72.1 Gy (SD 2.7) to PET GTV-N. 
CTV-total obtained an average mean dose of 75.8 Gy (SD 
4.1). Normal tissue doses were similar for the experimental 
and standard plan (Table 1). The maximum dose for the 
standard plans was 72.6 Gy (110%). Higher doses were 
applied for the experimental plans, but only to small volumes 
respecting the strict normal tissue constraints (see figure). 
 
 
 
Conclusion: A dose escalation trial with strict QA has been 
set up. Patient enrolment started January 2015. Analysis of 
the first 20 patients demonstrates that the escalation goals 
were met for the target and that dose to OARs were similar 
for the standard and the experimental treatment plans.  
 
OC-0545  
Results of a national audit of IMRT and VMAT patient QA 
E. Seravalli
1UMC Utrecht, Department of Radiation Oncology, Utrecht, 
The Netherlands 
1, A.C. Houweling2, M.P.R. Van Gellekom3, J. 
Kaas4, M. Kuik5, E.A. Loeff6, T.A. Raaben7, J.A. De Pooter8, 
J.H.W. De Vries9, J.B. Van de Kamer4 
2Academic Medical Center, Department of Radiation 
Oncology, Amsterdam, The Netherlands 
3Radiotherapiegroep, Department of Medical Physics, 
Arnhem, The Netherlands 
4The Netherlands Cancer Institute, Department of Radiation 
Oncology, Amsterdam, The Netherlands 
5Medisch Centrum Alkmaar, Department of Radiotherapy, 
Alkmaar, The Netherlands 
6Erasmus MC-Cancer Institute, Department of Radiation 
Oncology, Rotterdam, The Netherlands 
S260                                                                                     ESTRO 35 2016 
 _____________________________________________________________________________________________________ 
7Medisch Spectrum Twente, Radiotherapy, Enschede, The 
Netherlands 
8VSL, VSL, Delft, The Netherlands 
9University Medical Centre Utrecht, Department of 
Radiotherapyy, Utrecht, The Netherlands 
 
Purpose or Objective: To independently validate patient-
specific quality assurance (QA) methods, clinically used in the 
Netherlands, for IMRT and VMAT plans using the same set of 
treatment plans for all institutes. 
 
Material and Methods: A set of treatment plans was devised: 
simple and more complex IMRT/VMAT and a stereotactic 
VMAT plan, all 6MV for both Varian and Elekta linacs. Ten 
plans were used for Varian linacs (5 for True Beam and 5 for 
Clinac) and 9 for Elekta linac(4 for MLCi and 5 for Agility). 
The plans were imported in the participating institute’s 
treatment planning system for dose computation on the CT 
scan of the audit phantom (provided by the audit team 
together with the plans). Additionally, 10x10 cm2 fields were 
made and computed on both phantoms. Next, the audit team 
performed measurements using the audit equipment. All 21 
Dutch radiotherapy institutes were audited. The 
measurements were performed using an ionization chamber 
(PinPoint, PTW), Gafchromic EBT3 film and a 2D ionization 
chamber array, all in an octagonal phantom (Octavius, PTW). 
Differences between the measured and computed dose 
distribution were investigated using a global gamma analysis 
with a 5%/1mm criterion for the stereotactic VMAT plan and 
3%/3mm for the other plans with a 95% pass rate tolerance. 
Additionally, the participating centres performed QA 
measurements of the same treatment plans according to 
their local protocol and equipment. 
 
Results: The average difference between the point 
measurement, at the centre of the phantom, and the planned 
dose is below 1% (range: (-4.0 – +2.0)%) independently on the 
plan type (table 1).  
 
 
 
As shown in figure 1 the average pass rate obtained from the 
array measurements is in good agreement (average 
difference: (0.4 ± 1.0)%) with the average pass rate of the QA 
measurements provided by the participating institutes 
performed with their equipment for all the plans except for 
the simple VMAT plan.  
 
 
 
For the latter, the pass rate obtained with the Octavius is 
influenced by the sensitivity variation of the array as a 
function of gantry angle. Seven institutes out of 21 had plans 
that failed the audit gamma analysis pass rate tolerance of 
95% while the institute’s QA outcome was within tolerance (1 
institute two plans, 6 institutes one plan). The film 
measurement results are still under investigation and 
therefore not presented in this abstract. 
 
Conclusion: The results demonstrate that such a national QA 
audit is feasible. The reported in-house QA results were 
consistent with the audit despite differences in dosimetry 
equipment and analysis methods. Of the 21 Dutch centres 
audited, 67% passed the gamma analysis test for all the plans 
measured with a 2D-array by the audit team showing 
acceptable implementation of IMRT and VMAT delivery.  
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Purpose or Objective: Radiotherapy with grids has previously 
been carried out with photon beams. The grid method is used 
as an attempt to exploit the clinical finding that normal 
tissue can tolerate higher doses as the irradiated volumes 
become smaller. In this work we investigated the possibilities 
to perform proton-beam grid therapy (PBGT) with millimeter-
wide proton beams by performing Monte Carlo simulations of 
dose distributions produced by such grids. We also prepared 
proton-grid treatment plans with a TPS, using real patient 
data and beam settings available at modern proton therapy 
centers. 
 
Material and Methods: Monte Carlo calculations were 
performed using TOPAS version 1.2.p2 in a 20x20x20 cm3 
water tank. The beam grids (each containing 4x4 proton 
beams arranged in a square matrix) were aimed towards a 
cubic target at the tank center. A total of 2x2 opposing grid 
angles were used. The target was cross-fired in an interlaced 
manner. A beam-size study was carried out to find a suitable 
elemental beam size regarding beam thinness, peak-to-
entrance dose ratio and lateral penumbra along the beam 
path. Dose distributions inside and outside of the target were 
calculated for beam center-to-center (c-t-c) separations 
inside the grids of 6, 8 and 10 mm. 
The TPS study was performed with Varian Eclipse. We re-
planned two patients (one liver cancer and one rectal cancer 
patient) already treated in the hospital with photon therapy 
with the suggested PBGT. The IMPT method was used to 
prepare these plans. The plan objectives were set to create a 
homogeneous dose inside the target. 
 
Results: A beam size of 3 mm (FWHM) at the tank surface 
was found suitable from a dosimetric point of view for the 
further studies. By interlacing simulated beam grids from 
several directions, a cubic and nearly homogeneous dose 
distribution could be achieved in the target (see Figure 1). 
The c-t-c distance was found to have a significant impact on 
the valley dose outside of the target and on the homogeneity 
of the target dose. In the TPS study, a rather uniform dose 
distribution could be obtained inside of the contoured PTV 
while preserving the grid pattern of the dose distribution 
outside of it. The latter finding could be important for tissue 
repair and recovery. 
 
